The Board of Directors of Sun Pharmaceutical Industries Limited has approved the appointment of Dr. Andreas Eugen Busch (DIN: 11699735) as an Independent Director for a term of five consecutive years, effective 12 May 2026, subject to the approval of shareholders. The decision was passed by a board resolution on 12 May 2026 and disclosed to stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A of Schedule III.

Profile of the Incoming Independent Director

Dr. Busch is a globally recognised leader in drug discovery and pharmaceutical R&D. He is presently serving as Chief Innovation Officer at Absci, where he is responsible for leading R&D, technical operations, and driving both internal and partner programs. His career spans senior R&D leadership roles at some of the world's foremost pharmaceutical companies, including Sanofi, Bayer, and Shire. His leadership has resulted in over 15 commercial drugs progressing from bench research to FDA approval, with several more in late-stage clinical development. Dr. Busch also holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe-University in Frankfurt, Germany, where he received his PhD in Pharmacology.

The key details of his appointment, as disclosed under the regulatory framework, are summarised below:

Committee Reconstitution

In a related development, the Board also approved changes to the composition of its committees. Following earlier intimations dated 31 January 2026, 04 April 2026, and 08 May 2026, Ms. Rama Bijapurkar is set to retire from the Board on 20 May 2026 upon completion of her term as an Independent Director. To ensure continuity in governance, the Board approved the appointment of Ms. Satyavati Berera (DIN: 05002709) as a member of both the Audit Committee and the Risk Management Committee, effective 12 May 2026.

Regulatory Compliance

The disclosures pertaining to Dr. Busch's appointment confirm that he is not related to any Director, Key Managerial Personnel, or promoter of Sun Pharmaceutical Industries Limited, and does not have any inter se relationship with any of the Directors of the Company. Additionally, he is not debarred from holding the office of Director pursuant to any order of SEBI or any other such authority, in accordance with BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE ref. no. NSE/CML/2018/24, both dated 20 June 2018. The regulatory filing was signed by Anoop Deshpande, Company Secretary and Compliance Officer (ICSI Membership No.: A23983).

Sun Pharmaceutical Industries Limited has successfully concluded its postal ballot process, resulting in the appointment of Ms. Satyavati Berera as an Independent Director of the company. The resolution was duly approved by shareholders with the requisite majority, marking the completion of a corporate governance exercise initiated through a formal Notice dated 07 April 2026.

Appointment Details

The following table summarises the key details of Ms. Satyavati Berera's appointment as Independent Director:

Postal Ballot Process

The postal ballot process was initiated pursuant to a Notice dated 07 April 2026, with the remote e-voting period commencing on 09 April 2026. The process was completed on 08 May 2026, upon which the resolution for Ms. Berera's appointment was confirmed as having received the requisite shareholder approval.

The details of the voting results have been submitted to the stock exchanges. The Scrutinizer's Report has been made available on the company's official website at www.sunpharma.com . The communication was signed by Anoop Deshpande, Company Secretary and Compliance Officer (ICSI Membership No.: A23983), on behalf of Sun Pharmaceutical Industries Limited.